StreetInsider.com News Articles

Xenetic Biosciences partner gets Israeli approval for lymphoma study

Thu, 04 Jun 2026 08:41:57 -0400

Xenetic Biosciences Inc. (NASDAQ: XBIO) announced that its collaboration partner PeriNess Ltd. received approval from the Israeli Ministry of Health to conduct a clinical study combining DNase I with anti-CD19 CAR T cells in large B-cell lymphoma patients.

The exploratory study will treat 12 patients with stable or progressive disease prior to lymphodepletion therapy. Participants will receive CAR T cells targeting CD19 in combination with DNase I administered through 50-ml IV infusions at 1.0 mg/kg on days 0, 3, 6, 10 and 15 after CAR T cell infusion.

The study will evaluate clinical efficacy through objective response rate at 1 and 3

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination

Thu, 04 Jun 2026 08:40:00 -0400

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion

Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers

Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")

FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination

Thu, 04 Jun 2026 08:40:00 -0400

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion

Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")

FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology

Xenetic Biosciences presents DNase I data at ASCO 2026 meeting

Mon, 01 Jun 2026 09:03:36 -0400

Xenetic Biosciences Inc. (NASDAQ: XBIO) presented preclinical data at the 2026 American Society of Clinical Oncology Annual Meeting showing that DNase I enhances CAR-T cell function in hematologic cancer models.

The poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," was presented on June 1, 2026, by Alexey V. Stepanov, PhD.

According to the company's findings, DNase I degraded extracellular DNA and preserved CAR-T cell function in laboratory studies. The treatment improved CD8-positive T cell ratios and reduced expression of exhaustion markers including PD-1, LAG-3 and TIM-3 across multiple rounds of tumor rechallenge in

Xenetic Biosciences presents DNase I data at ASCO 2026 meeting

Mon, 01 Jun 2026 09:03:36 -0400

The poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," was presented on June 1, 2026, by Alexey V. Stepanov, PhD.

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

Mon, 01 Jun 2026 09:02:00 -0400

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies

Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models

Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers

Data to be presented today as a poster presentation at the ASCO 2026 annual meeting

FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

Mon, 01 Jun 2026 09:02:00 -0400

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies

Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models

Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers

Data to be presented today as a poster presentation at the ASCO 2026 annual meeting

FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"

Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575016.html

Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575016.html

Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575016.html

Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575016.html

Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 14 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26496140.html

Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 14 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26496140.html

Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 14 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26496140.html

Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 14 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26496140.html

Form 8-K Xenetic Biosciences, For: May 13